Compare ACADIA Pharmaceuticals Inc. (ACAD) vs The Vita Coco Company Inc (COCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs The Vita Coco Company Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while The Vita Coco Company Inc trades at $66.62 (market cap $3.74B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ACAD | COCO | |
|---|---|---|
Market Cap | $4.49B | $3.74B |
Sector | Health | Technology |
52-Week High | $28.06 | $84.02 |
52-Week Low | $20.06 | $32.30 |
Enterprise Value | $3.69B | $3.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
COCO trades at $66.78, up 0.94% today, with a bullish technical signal driven by oversold RSI readings but bearish moving averages. The company reported strong Q1 2026 EPS of $0.50, beating expectations, and shows robust profitability with a 12.59% net margin and 26.32% ROE. Recent news highlights market dominance in coconut water and expanded partnerships, supporting growth prospects amid a $125 billion market opportunity.
Outlook is positive with a consensus price target of $79.33, implying 19% upside, though high valuation multiples (P/E 48.39) and competitive pressures pose risks. Investors should weigh strong earnings momentum against potential volatility from sector rotation and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →
